| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|
histamine
[no description available] | 1.99 | 1 | 0 | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter |
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity. | 3.09 | 1 | 0 | acetophenones;
aromatic ether;
phenols;
tetrazoles | anti-asthmatic drug;
leukotriene antagonist |
pentoxifylline
[no description available] | 1.99 | 1 | 0 | oxopurine | |
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist | 3.09 | 1 | 0 | chromones | |
pf 5901
alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: structure given in first source; platelet activating factor antagonist | 3.09 | 1 | 0 | quinolines | |
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist | 3.49 | 2 | 0 | carbamate ester;
indoles;
N-sulfonylcarboxamide | anti-asthmatic agent;
leukotriene antagonist |
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES. | 1.99 | 1 | 0 | indazole | |
ablukast
[no description available] | 3.09 | 1 | 0 | | |
zileuton
[no description available] | 3.09 | 1 | 0 | 1-benzothiophenes;
ureas | anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug |
wy 48252
Wy 48252: leukotriene D4 antagonist | 3.09 | 1 | 0 | | |
pobilukast
pobilukast: a leukotriene receptor antagonist; an antiasthmatic agent; structure in first source; RN refers to (R-(R*,S*)-isomer | 3.09 | 1 | 0 | | |
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors | 3.09 | 1 | 0 | aromatic ketone | |
sc 41930
SC 41930: leukotriene B4 receptor antagonist; structure in first source | 3.09 | 1 | 0 | | |
ici 198615
ICI 198615: an LTD4 receptor antagonist; SRS-A antagonist; structure given in first source | 1.99 | 1 | 0 | | |
l 648051
L 648051: antagonist of leukotriene D4 receptor; structure in first source | 3.09 | 1 | 0 | | |
ly 255283
LY 255283: structure given in UD; leukotriene B4 antagonist | 3.09 | 1 | 0 | aromatic ketone | |
bay x 1005
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source; | 3.09 | 1 | 0 | | |
sr 2640
SR 2640: leukotriene D4 and E4 antagonist | 3.09 | 1 | 0 | quinolines | |
rg 12525
RG 12525: leukotriene D4 antagonist; structure in first source | 3.09 | 1 | 0 | | |
ici d2138
ICI D2138: structure given in first source; inhibitor of leukotriene B4 synthesis | 3.09 | 1 | 0 | | |
ly 293111
LY 293111: a leukotriene B4 receptor antagonist; structure given in first source | 3.09 | 1 | 0 | aromatic ether | |
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2h-1-benzopyran-2-propanoic acid
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid: structure in first source; inhibits leukotriene B4 receptors | 3.09 | 1 | 0 | | |
via 2291
atreleuton: structure given in first source | 3.09 | 1 | 0 | | |
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase. | 3.09 | 1 | 0 | aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes | antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist |
leukotriene c4
Leukotriene C4: The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene C4 : A leukotriene that is (5S,7E,9E,11Z,14Z)-5-hydroxyicosa-7,9,11,14-tetraenoic acid in which a glutathionyl group is attached at position 6 via a sulfide linkage. | 1.98 | 1 | 0 | leukotriene | bronchoconstrictor agent;
human metabolite;
mouse metabolite |
thromboxane a2
Thromboxane A2: An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).. thromboxane A2 : A thromboxane which is produced by activated platelets and has prothrombotic properties: it stimulates activation of new platelets as well as increases platelet aggregation. | 1.99 | 1 | 0 | epoxy monocarboxylic acid;
thromboxanes A | mouse metabolite |
leukotriene d4
Leukotriene D4: One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene D4 : A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R). | 10.19 | 6 | 2 | dipeptide;
leukotriene;
organic sulfide | bronchoconstrictor agent;
human metabolite;
mouse metabolite |
montelukast
montelukast: a leukotriene D4 receptor antagonist | 3.09 | 1 | 0 | aliphatic sulfide;
monocarboxylic acid;
quinolines | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist |
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3. | 3.37 | 1 | 1 | cysteinium | fundamental metabolite |
sb 201993
(E)-3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid: structure given in first source; a competitive LTB(4) receptor antagonist | 3.09 | 1 | 0 | | |
bwa 4c
[no description available] | 3.09 | 1 | 0 | | |
ono 4057
ONO-LB 457: LTB4 receptor antagonist; structure given in first source | 3.09 | 1 | 0 | | |
ticolubant
Ticolubant: a leukotriene B4 antagonist | 3.09 | 1 | 0 | | |
ly 223982
LY 223982: RN & structure in first source; leukotriene B4 antagonist | 3.09 | 1 | 0 | | |
verlukast
verlukast: LTD4 receptor antagonist | 1.99 | 1 | 0 | | |
cp 105696
CP 105696: a leukotriene B4 receptor antagonist; structure in first source | 3.09 | 1 | 0 | | |
mk 0571
[no description available] | 3.09 | 1 | 0 | | |